Navigation Links
Andain Inc. Announces Successful 510K Tests of its Breakthrough Miniature Disposable Insulin Pump
Date:4/10/2013

BEVERLY HILLS, California, April 10, 2013 /PRNewswire/ --

Andain Inc. (OTCQB: ANDN) ("Andain"), a company engaged in commercializing novel technologies in biotech, medical and life sciences fields through its accelerating incubator program, announces today of the successful 510K tests of its miniature disposable insulin pump.

Andain Inc. has successfully completed all of the required tests for the 510K regulation of its innovative miniature disposable insulin pump.

Andain's miniature disposable insulin pump is an ultra slim, small 'Band-Aid' patch size, fully disposable, water proof, fully programmable insulin pump designed to treat Type I and Type II diabetes for a one week period. The pump's dimensions are 49mm diameter by 7 mm thick 25 with 6CC insulin, making it very comfortable and almost unnoticeable to wear. Its ultra-low cost makes it an affordable yet clinically superior replacement for pen injector products. Smart on-line monitoring provides a real-time alert for occlusions and leakages.

The pump plug-in universal remote-control (PUR) unit provides the user, clinic, and doctor a dynamic control and on-going monitoring of the insulin treatment program.

 "Our expert team meticulously monitored all tests process and results for the 510K regulation process, and providing full safety for our diabetics type II planed clinical trials."  said Andain President and CEO Sam Elimelech .

Established in 2004 as a Nevada corporation with locations in Israel and the US, Andain Inc. (OTCBB: ANDN) commercializes novel technologies in the biotech & medical fields, specializing in identifying technical innovations and providing a unique incubator/accelerator development and industrial platform. The company also offers technical know-how and business strategy expertise to commercialize new technologies and deliver shareholder value

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Form 10-K filing and other filings with the U S. Securities and Exchange Commission (available at http://www.sec.gov/). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Contact:

Sam Elimelech
CEO
sam@andaininc.com
+972-52-67-22212


'/>"/>
SOURCE Andain Inc
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Andain Inc. the Innovative Technology Incubator, Receives DTC Eligibility
2. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
3. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
4. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
5. Misonix Announces New Distribution Agreement For Panama
6. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
9. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
10. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
11. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... , July 11, 2017 Zymo Research Corp., also known ... that can quantify biological aging in a precise manner using the myDNAge ... Steve Horvath , a professor of human genetics and biostatistics at the ... School of Public Health , Zymo Research,s proprietary DNAge ™ technology ... ...
(Date:7/11/2017)... 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery ... Administration (FDA) has agreed to schedule an End-of-Phase II ... trial of its oral insulin capsule ORMD-0801 in the ... met primary and secondary endpoints by indicating a statistically ...
(Date:7/10/2017)... 2017 Locus Biosciences Inc. today announced the ... development of CRISPR-Cas3 antimicrobial therapeutics. Financing for the round ... Internet services provider, and joined by the North Carolina ... product programs targeting antibiotic resistant infections and other microbiome-related ... Dr. Rodolphe Barrangou and Dr. Charles ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... 20, 2017 , ... The Business Architecture Guild® is pleases ... Guide )v 6.0 is now available for member download. This release is dedicated ... , Non-members may download the Part 1 Introduction for free at ...
(Date:7/20/2017)... NC (PRWEB) , ... July 20, 2017 , ... LINET, ... the latest innovation to their product line: the AVE 2 birthing bed. , Perfectly ... helps bring a new level of comfort and efficiency to every phase of childbirth. ...
(Date:7/20/2017)... ... July 19, 2017 , ... At Creekwood Dental Arts, Drs. Donna G. ... treatment and dental implants in Waco, TX, using the latest dental technology ... by Tekscan®, they can capture details in the oral cavity for accurate diagnoses and ...
(Date:7/20/2017)... ... July 19, 2017 , ... Adolfson & Peterson ... manager, Josh Christensen. As a leader in healthcare construction, AP has successfully built ... resume in the Midwest with Josh now on board. , Josh brings ...
(Date:7/20/2017)... ... ... “Fidget”: a fun-filled, action-packed memoir of adventures. “Fidget” is the creation of ... who was a summa cum laude graduate of Gardner Webb University. She has won ... her retirement from public school, Lynn continued to pursue her love for music through ...
Breaking Medicine News(10 mins):